NEW YORK (GenomeWeb News) – Mirna Therapeutics will test the effect of its proprietary miRNA mimics on a panel of Horizon Discovery's human isogenic cancer cell models, under a collaboration announced today.
Under the deal, Horizon's X-Man human discovery cell lines will be used to test the effects of common mutations in cancer patients on the efficacy of Mirna's miRNA mimics.
The project is being funded partly by a Cancer Prevention and Research Institute of Texas commercialization grant. Other terms of the deal were not disclosed.
In a statement, Paul Lammers, president and CEO of Mirna, said the partnership will "increase the understanding of how our highly potent tumor suppressor miRNA mimics act under human cancer cells characterized by different disease-causing mutations," which in turn will help the company to better define the best patient population for clinical trials.